Molecular therapy for Metabolic disorders: MiRNA-152 increases (LXR)-α expression, insulin-secreting cell mass and function via down regulation of its target genes, 24/November/2016, 1.27 pm

Molecular therapy for Metabolic disorders: MiRNA-152 increases (LXR)-α expression, insulin-secreting cell mass and function via down regulation of its target genes, 24/November/2016, 1.27 pm

Molecular therapy for Metabolic disorders: MiRNA-152 increases (LXR)-α expression, insulin-secreting cell mass and function via down regulation of its target genes, 24/November/2016, 1.27 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Public health relevance: 

Given that (1)  more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) the life-long painful injection/drug treatment required to treat DM; and (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult β-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug.


From research findings to therapeutic opportunity:

This study suggests an MiRNA-based Regenerative therapy for DM.  MiRNA-152, by decreasing the expression of its target gene,  it may: (1) increase the expression of modulator of lipid homeostasis liver X receptor (LXR)-α; (2) decrease plasma levels of triglyceride and cholesterol; (3) protect against diet-induced weight-gain; and (4) increase insulin-secreting cell mass and function. price-50

Thereby, it may increase insulin sensitivity and leanness.  Thus, pharmacological formulations encompassing “MiRNA-152 or its activators or MiRNA-152 plus any of the known anti-metabolic compounds in use”  can be used to treat metabolic disorders, including DM.


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How MiRNA-152 increases: (1) (LXR)-α expression; (2) and insulin-secreting cell mass and function. 

Amount: $50

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Citation: Boominathan, L., Molecular therapy for Metabolic disorders: MiRNA-152  increases (LXR)-α expression, insulin-secreting cell mass and function via down regulation of its target genes, 24/November/2016, 1.28 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org